|
| Status |
Public on Jun 16, 2021 |
| Title |
RNAseq data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
RNAseq data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds.
|
| |
|
| Overall design |
RNAseq data of 12 samples (niraparib arm (n=3) or source tumor arm (n=2) ) in three independent experiments for four drug treaments cycles.
|
| |
|
| Contributor(s) |
Kaufmann S |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Dec 24, 2020 |
| Last update date |
Jun 16, 2021 |
| Contact name |
Hu Li |
| E-mail(s) |
li.hu@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Department |
Molecular Pharmacology & Experimental Therapeutics
|
| Lab |
Systems Biology and Pharmacology
|
| Street address |
200 First Street, Gonda Building G19-408
|
| City |
Rochester |
| State/province |
MN |
| ZIP/Postal code |
55904 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (12)
|
| GSM4988749 |
P2A1: Sensitive PH039 third passage source tumor |
| GSM4988750 |
P2A2: Sensitive PH039 third passage source tumor |
| GSM4988751 |
P2A3: Sensitive PH039 third passage source tumor |
| GSM4988752 |
F1A3: Sensitive PH039 first passage niraparib treated tumor |
| GSM4988753 |
F1A4: Sensitive PH039 first passage niraparib treated tumor |
| GSM4988754 |
F1A5: Mixed phenotype PH039 first passage niraparib treated tumor |
| GSM4988755 |
F251: Mixed phenotype PH039 first passage niraparib treated tumor |
| GSM4988756 |
F351: Resistant PH039 second passage niraparib treated tumor |
| GSM4988757 |
F352: Resistant PH039 second passage niraparib treated tumor |
| GSM4988758 |
F451: Resistant PH039 third passage niraparib treated tumor |
| GSM4988759 |
F452: Resistant PH039 third passage niraparib treated tumor |
| GSM4988760 |
F453: Resistant PH039 third passage niraparib treated tumor |
|
| This SubSeries is part of SuperSeries: |
| GSE165052 |
Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development |
|
| Relations |
| BioProject |
PRJNA687759 |
| SRA |
SRP299302 |
Less...
More...